Dr. Halayko leads a long-standing and internationally recognized research program for asthma pathogenesis using in vitro and animal disease models with multi-omics technologies for pre-clinical studies.

His program has evolved from one with focus only on cell and molecular mechanisms for phenotype diversity of airway smooth muscle, to one that integrates translational research with a focus on real world unmet clinical issues.

He uses biomarker research – transcriptomics, proteomics and lipidomics – taking data from human cohorts, and validating their pathobiological significance in cell and animal models.

Including his main focus on asthma, he also has projects linked to COPD, pulmonary fibrosis, the response to inhaled pollutants, host response to viral infection (including SARS CoV2), and the developmental origins of lung disease.

Collectively, the basic science, translational research, and clinical epidemiology approaches he uses are frequently part of local and national collaborations.